calcium binding protein 4Genealiases: CRSD · CSNB2B
Q-omics provides the consensus-scored CABP4 profile across patient tissues and cancer cell-line models. CABP4 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CABP4 is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, CABP4 RNA expression shows 15,496 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and KICH as cancer lineages where CABP4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CABP4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CABP4 survival associations across molecular data types. CABP4 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CABP4 RNA expression–survival associations across cancer types. High CABP4 expression shows unfavorable associations in UVM, LGG, LIHC and OV, but favorable associations in BLCA and COAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify UVM as the clearest survival context for CABP4 RNA expression.
This table summarizes CABP4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for CABP4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CABP4 shows lower tumor expression in KICH and LUSC and higher tumor expression in COAD, UCEC, STAD and BLCA. The KICH box plot shows higher CABP4 RNA expression in normal versus tumor tissue (log2 FC = −1.088, t-test p < 0.001).
This table shows molecular features associated with CABP4 in patient tissues and cancer cell lines. In patient samples, CABP4 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CABP4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
